Electrocore Earnings Call Highlights Growth Amid Losses

Electrocore ((ECOR)) has held its Q1 earnings call. Read on for the main highlights of the call.

Electrocore’s latest earnings call struck an optimistic tone, as management balanced record financial performance with a candid discussion of risks. Revenue hit new highs, margins expanded sharply, and adjusted EBITDA losses narrowed, while leadership reaffirmed full‑year guidance and highlighted multiple growth catalysts across the VA, consumer wellness, and international markets.

Record Revenue Underscores Accelerating Growth

Electrocore delivered its strongest quarter ever with Q1 2026 revenue of $9.6 million, up 43% year over year and setting a new top‑line benchmark. Management reiterated its outlook for roughly 30% revenue growth for the full year, implying $9 million to $10 million of incremental sales on top of 2025’s $32 million base.

Margin Expansion Signals Emerging Operating Leverage

Gross profit reached $8.4 million as gross margin widened to 87%, a 200 basis point improvement versus last year, underscoring pricing power and manufacturing efficiency. Adjusted EBITDA loss narrowed to $2.3 million from $3.1 million, a 24% improvement that points to growing scale benefits even as the company invests in growth.

VA Channel Drives Core Prescription Momentum

VA prescription device revenue climbed 48% year over year to $7.9 million, cementing the Veterans Affairs system as Electrocore’s primary growth engine. Roughly 15,000 VA patients have now received gammaCore, yet this represents only about 2.5% penetration of the addressable VA headache market, suggesting a long runway for expansion.

Consumer Wellness and TruVega Gain Traction

The consumer wellness segment posted $1.6 million in revenue, up 44% year over year, driven largely by TruVega’s $1.5 million contribution, which grew 38%. Return on advertising spend improved to about 2.37, up 14% sequentially, while product return rates held steady at 12% to 15%, indicating improving marketing efficiency without eroding customer satisfaction.

Quell Integration and Product Strategy Advance

Quell posted its first quarter above $1 million in sales, bringing cumulative revenue since acquisition to approximately $2.5 million to $2.7 million, most of it from fibromyalgia prescriptions in the VA. Management outlined plans for a measured relaunch of Quell Relief in the over‑the‑counter market later this year, positioning the brand for broader consumer adoption.

New Leadership and R&D Catalysts Support Growth

A new chief operating officer, Mike Fox, brings deep federal and commercial expertise, with priorities including deeper VA penetration and expanded Department of Defense and broader federal channels. On the innovation front, TACSTIM is involved in multiple DoD research efforts, the Acacia PTSD study is enrolling, PTSD carries Breakthrough Device status, and TruVega launched in the U.K. in January 2026.

GAAP Losses Heavier on One‑Time Transition Costs

Despite operational gains, GAAP net loss widened to $5.3 million in Q1 2026 from $3.9 million a year earlier, with net loss per share rising to $0.59 from $0.47. Management emphasized that $1.9 million of leadership transition charges drove much of the deterioration, and excluding those items, net loss per share would have been approximately $0.37.

Cash Burn and Balance Sheet Remain Watch Points

Cash, cash equivalents and marketable securities fell to about $8.8 million at March 31, 2026, from $11.6 million at year‑end, a roughly 24% decline that reflects the company’s ongoing investment needs. Management noted that the first quarter is typically the heaviest cash‑burn period and flagged that inventory and capital projects could keep burn elevated into Q2, leaving investors alert to funding timing.

Operating Losses Persist as SG&A Stays Elevated

Even with improved metrics, adjusted EBITDA remained negative at $2.3 million, underscoring that Electrocore is still in investment mode. Selling, general and administrative expenses totaled $12.9 million, including $1.9 million of one‑time leadership transition costs and about $300,000 in legal spending tied to intellectual property litigation, all of which weigh on near‑term profitability.

Low Penetration Highlights Both Risk and Opportunity

GammaCore’s estimated 2.5% penetration of the VA headache market and relatively concentrated Quell prescribing—Quell is used in roughly one‑third as many facilities as gammaCore—underscore how early Electrocore is in its adoption curve. This limited breadth and depth represent a risk if growth stalls, but also suggest substantial upside if sales forces can broaden coverage and physician awareness.

TACSTIM Variability Adds Execution Risk

Management acknowledged that TACSTIM revenue remains historically inconsistent and not yet a dependable contributor to the top line. Future commercial traction in TACSTIM and wider federal channels hinges on ongoing research outcomes and contract wins, leaving timing and scale of these potential contributions uncertain for now.

Guidance Reaffirmed on Back of High‑Growth Quarter

Looking ahead, leadership reaffirmed its forecast for about 30% revenue growth in 2026, implying roughly $41.6 million in sales supported by Q1’s 43% surge and mid‑80s gross margins. Management pointed to VA and federal expansion, TruVega and Quell rollouts, TACSTIM upside, and a next‑generation mobile platform targeted for 2027 as key drivers behind the outlook, even as they stopped short of signaling a near‑term breakeven quarter.

Electrocore’s call leaves investors weighing strong growth and expanding margins against ongoing losses and a shrinking cash pile. For now, accelerating VA adoption, rising consumer wellness sales, and a pipeline of R&D and product catalysts tilt the narrative positive, but execution on channel expansion and disciplined cost control will determine whether today’s momentum translates into sustainable profitability.